Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.
You may also be interested in...
From the approval of AZT to the generic drug scandal, Frank Young oversaw many seminal events at US FDA while commissioner from 1984 to 1989. After leaving the agency, he managed the approval of the NDA for Braeburn's opioid dependence drug Probuphine. Young passed away following a short bout with cancer.
Senate legislation may be influenced by movement to push through Califf’s nomination for FDA commissioner.
Susan Mayne brings “new strength and focus to CFSAN” and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.